Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed...Stock Purchase Agreement • May 6th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Delaware
This Stock Purchase Agreement (this “Agreement”) is made and entered into as of October 1, 2014, by and among OnCore Biopharma, Inc., a Delaware corporation (“Buyer”), and Pharmabridge, Inc., a Pennsylvania corporation, and Hepatitis B Foundation, a Pennsylvania non-profit foundation (each, a “Stockholder” and together, the “Stockholders”).
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed...Collaboration and Funding Agreement • May 6th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Pennsylvania
This Research Collaboration and Funding Agreement (this “Agreement”), is entered into by and between OnCore Biopharma, Inc., a Delaware corporation (“Company”), and the Baruch S. Blumberg Institute, a Pennsylvania not-for-profit company (“Institution”), as of October 29, 2014 (the “Effective Date”).
LICENSE AGREEMENT by and between NEUROVIVE PHARMACEUTICAL AB and ONCORE BIOPHARMA, INC.License Agreement • May 6th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • England and Wales
This License Agreement (this “Agreement”) dated the 8th day of September 2014 (the “Effective Date”) is by and between NeuroVive Pharmaceutical AB, a company organized under the laws of Sweden (“NeuroVive”), and OnCore Biopharma, Inc., a Delaware corporation (“OnCore”). NeuroVive and OnCore may each be referred to herein individually as a “Party” and collectively as the “Parties”.
